Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 16.1 USD -6.56% Market Closed
Market Cap: 865.9m USD
Have any thoughts about
Prothena Corporation PLC?
Write Note

Intrinsic Value

PRTA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PRTA stock under the Base Case scenario is 44.76 USD. Compared to the current market price of 16.1 USD, Prothena Corporation PLC is Undervalued by 64%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PRTA Intrinsic Value
44.76 USD
Undervaluation 64%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Prothena Corporation PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PRTA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PRTA?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Prothena Corporation PLC

Provide an overview of the primary business activities
of Prothena Corporation PLC.

What unique competitive advantages
does Prothena Corporation PLC hold over its rivals?

What risks and challenges
does Prothena Corporation PLC face in the near future?

Has there been any significant insider trading activity
in Prothena Corporation PLC recently?

Summarize the latest earnings call
of Prothena Corporation PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Prothena Corporation PLC.

Provide P/S
for Prothena Corporation PLC.

Provide P/E
for Prothena Corporation PLC.

Provide P/OCF
for Prothena Corporation PLC.

Provide P/FCFE
for Prothena Corporation PLC.

Provide P/B
for Prothena Corporation PLC.

Provide EV/S
for Prothena Corporation PLC.

Provide EV/GP
for Prothena Corporation PLC.

Provide EV/EBITDA
for Prothena Corporation PLC.

Provide EV/EBIT
for Prothena Corporation PLC.

Provide EV/OCF
for Prothena Corporation PLC.

Provide EV/FCFF
for Prothena Corporation PLC.

Provide EV/IC
for Prothena Corporation PLC.

Show me price targets
for Prothena Corporation PLC made by professional analysts.

What are the Revenue projections
for Prothena Corporation PLC?

How accurate were the past Revenue estimates
for Prothena Corporation PLC?

What are the Net Income projections
for Prothena Corporation PLC?

How accurate were the past Net Income estimates
for Prothena Corporation PLC?

What are the EPS projections
for Prothena Corporation PLC?

How accurate were the past EPS estimates
for Prothena Corporation PLC?

What are the EBIT projections
for Prothena Corporation PLC?

How accurate were the past EBIT estimates
for Prothena Corporation PLC?

Compare the revenue forecasts
for Prothena Corporation PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Prothena Corporation PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Prothena Corporation PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Prothena Corporation PLC compared to its peers.

Compare the P/E ratios
of Prothena Corporation PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Prothena Corporation PLC with its peers.

Analyze the financial leverage
of Prothena Corporation PLC compared to its main competitors.

Show all profitability ratios
for Prothena Corporation PLC.

Provide ROE
for Prothena Corporation PLC.

Provide ROA
for Prothena Corporation PLC.

Provide ROIC
for Prothena Corporation PLC.

Provide ROCE
for Prothena Corporation PLC.

Provide Gross Margin
for Prothena Corporation PLC.

Provide Operating Margin
for Prothena Corporation PLC.

Provide Net Margin
for Prothena Corporation PLC.

Provide FCF Margin
for Prothena Corporation PLC.

Show all solvency ratios
for Prothena Corporation PLC.

Provide D/E Ratio
for Prothena Corporation PLC.

Provide D/A Ratio
for Prothena Corporation PLC.

Provide Interest Coverage Ratio
for Prothena Corporation PLC.

Provide Altman Z-Score Ratio
for Prothena Corporation PLC.

Provide Quick Ratio
for Prothena Corporation PLC.

Provide Current Ratio
for Prothena Corporation PLC.

Provide Cash Ratio
for Prothena Corporation PLC.

What is the historical Revenue growth
over the last 5 years for Prothena Corporation PLC?

What is the historical Net Income growth
over the last 5 years for Prothena Corporation PLC?

What is the current Free Cash Flow
of Prothena Corporation PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Prothena Corporation PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Prothena Corporation PLC

Current Assets 586m
Cash & Short-Term Investments 564.1m
Other Current Assets 21.9m
Non-Current Assets 59.6m
PP&E 15.6m
Other Non-Current Assets 44m
Current Liabilities 46.7m
Accounts Payable 9.3m
Accrued Liabilities 27.9m
Other Current Liabilities 9.5m
Non-Current Liabilities 16.9m
Other Non-Current Liabilities 16.9m
Efficiency

Earnings Waterfall
Prothena Corporation PLC

Revenue
217.3m USD
Operating Expenses
-308.6m USD
Operating Income
-91.4m USD
Other Expenses
40.4m USD
Net Income
-50.9m USD

Free Cash Flow Analysis
Prothena Corporation PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

The company ended 2023 with $621 million in cash, strengthening its financial stability. They are progressing with PRX012 in a phase I trial, aiming for a dose that would permit entry into a registration-enabling study. Birtamimab's AFFIRM AL trial remains pivotal, with FDA approval pending results that demonstrate a significant impact on all-cause mortality (p ≤ 0.1). Revenue growth for the next year is expected to be flat, as management focuses on strategic priorities rather than short-term revenue maximization, while operating margin is forecasted to improve slightly.

What is Earnings Call?
Fundamental Scores

PRTA Profitability Score
Profitability Due Diligence

Prothena Corporation PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Negative ROE
27/100
Profitability
Score

Prothena Corporation PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

PRTA Solvency Score
Solvency Due Diligence

Prothena Corporation PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Prothena Corporation PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PRTA Price Targets Summary
Prothena Corporation PLC

Wall Street analysts forecast PRTA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRTA is 62.37 USD with a low forecast of 24.24 USD and a high forecast of 98.7 USD.

Lowest
Price Target
24.24 USD
51% Upside
Average
Price Target
62.37 USD
287% Upside
Highest
Price Target
98.7 USD
513% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PRTA?

Click here to dive deeper.

Dividends

Prothena Corporation PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for PRTA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PRTA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

PRTA News

Other Videos

Profile

Prothena Corporation PLC Logo
Prothena Corporation PLC

Country

Ireland

Industry

Biotechnology

Market Cap

865.7m USD

Dividend Yield

0%

Description

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

Contact

DUBLIN
77 Sir John Rogersons Quay, Block C, Grand Canal Docklands
+35312362500.0
www.prothena.com

IPO

2012-12-21

Employees

82

Officers

President, CEO & Director
Dr. Gene G. Kinney Ph.D.
CFO & Chief Strategy Officer
Mr. Tran B. Nguyen M.B.A.
Chief Operating Officer
Mr. Brandon S. Smith
Chief Regulatory Officer
Ms. Carol D. Karp
Chief Accounting Officer & Controller
Ms. Karin L. Walker CPA
Chief Scientific Officer
Dr. Wagner M. Zago
Show More
Vice President of Investor Relations
Mr. Mark C. Johnson C.F.A.
Chief Legal Officer
Mr. Michael J. Malecek
Chief People Officer
Mr. David A. Ford
Chief Development Officer
Dr. Chad J. Swanson Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one PRTA stock?

The intrinsic value of one PRTA stock under the Base Case scenario is 44.76 USD.

Is PRTA stock undervalued or overvalued?

Compared to the current market price of 16.1 USD, Prothena Corporation PLC is Undervalued by 64%.

Back to Top